← All trials
NCT05763602
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2022
- Primary completion
- Feb 15, 2025
- Completion date
- May 31, 2025
- First posted
- Mar 10, 2023
- Last posted
- Mar 13, 2023
- Enrollment
- 2000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of IowaLead sponsor
- Centers for Disease Control and Prevention (CDC)Collaborator
- Emory UniversityCollaborator
- Indiana UniversityCollaborator
- University of IowaOverall official - principal investigator
- University of IowaSponsor investigator
- University of Texas, GalvestonCollaborator
- University of UtahCollaborator
- Washington University in St. LouisCollaborator
- PDI HealthcareCollaborator
- University of IowaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.